Flagship Pioneering Inc. - Q3 2016 holdings

$366 Million is the total value of Flagship Pioneering Inc.'s 9 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was - .

 Value Shares↓ Weighting
MCRB NewSERES THERAPEUTICS INC$155,873,00012,682,876
+100.0%
42.59%
SYRS NewSYROS PHARMACEUTICALS INC$66,668,0004,806,656
+100.0%
18.22%
AGIO NewAGIOS PHARMACEUTICALS INC$50,991,000965,369
+100.0%
13.93%
EDIT NewEDITAS MEDICINE INC$46,578,0003,455,316
+100.0%
12.73%
SELB NewSELECTA BIOSCIENCES INC$23,539,0001,651,862
+100.0%
6.43%
TTOO NewT2 BIOSYSTEMS INC$15,756,0002,176,167
+100.0%
4.30%
EBIO NewELEVEN BIOTHERAPEUTICS INC$6,594,0002,354,710
+100.0%
1.80%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2016-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
SERES THERAPEUTICS INC29Q3 202368.0%
DENALI THERAPEUTICS INC24Q3 202350.9%
SYROS PHARMACEUTICALS INC24Q2 202227.3%
MODERNA INC20Q3 202376.9%
EVELO BIOSCIENCES INC20Q1 202341.2%
RUBIUS THERAPEUTICS INC18Q4 202260.7%
Axcella Health Inc17Q2 20233.5%
KALEIDO BIOSCIENCES INC13Q1 20229.5%
Foghorn Therapeutics Inc12Q3 20236.5%
Sana Biotechnology Inc11Q3 202318.4%

View Flagship Pioneering Inc.'s complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
42024-02-14
13F-HR2023-11-14
42023-09-15
42023-08-15
13F-HR2023-08-14
42023-07-13
13F-HR2023-05-15
42023-02-27
13F-HR2023-02-14

View Flagship Pioneering Inc.'s complete filings history.

Compare quarters

Export Flagship Pioneering Inc.'s holdings